{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T13:24:02Z","timestamp":1758893042172},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T00:00:00Z","timestamp":1473206400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Key Project of Tianjin","award":["14ZCZDSY00013"],"award-info":[{"award-number":["14ZCZDSY00013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Biochem Biotechnol"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s12010-016-2225-2","type":"journal-article","created":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T09:20:24Z","timestamp":1473240024000},"page":"483-494","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacological Effects and Pharmacokinetic Properties of a Dual-Function Peptide 5rolGLP-HV"],"prefix":"10.1007","volume":"181","author":[{"given":"Zaizhong","family":"Ni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofeng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haisong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huikun","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pingzhe","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peipei","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minggang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,7]]},"reference":[{"issue":"5","key":"2225_CR1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cmet.2010.04.009","volume":"11","author":"E Ferrannini","year":"2010","unstructured":"Ferrannini, E. (2010). The stunned beta cell: a brief history. Cell Metabolism, 11(5), 349\u2013352.","journal-title":"Cell Metabolism"},{"issue":"5","key":"2225_CR2","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.bmc.2009.01.061","volume":"17","author":"SH Havale","year":"2009","unstructured":"Havale, S. H., & Pal, M. (2009). Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. Bioorganic & Medicinal Chemistry, 17(5), 1783\u20131802.","journal-title":"Bioorganic & Medicinal Chemistry"},{"issue":"3","key":"2225_CR3","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/ilar.47.3.234","volume":"47","author":"MS Henson","year":"2006","unstructured":"Henson, M. S., & O'Brien, T. D. (2006). Feline models of type 2 diabetes mellitus. ILAR Journal, 47(3), 234\u2013242.","journal-title":"ILAR Journal"},{"key":"2225_CR4","doi-asserted-by":"crossref","unstructured":"Sharma, A. K., Bharti, S., Goyal, S., Arora, S., Nepal, S., Kishore, K., et al. (2011). Upregulation of PPARgamma by Aegle marmelos ameliorates insulin resistance and beta-cell dysfunction in high fat diet fed-streptozotocin induced type 2 diabetic rats. Phytotherapy Research, 25(10), 1457\u20131465.","DOI":"10.1002\/ptr.3442"},{"issue":"1","key":"2225_CR5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12010-014-1014-z","volume":"174","author":"M Honardoost","year":"2014","unstructured":"Honardoost, M., Sarookhani, M. R., Arefian, E., & Soleimani, M. (2014). Insulin resistance associated genes and miRNAs. Applied Biochemistry and Biotechnology, 174(1), 63\u201380.","journal-title":"Applied Biochemistry and Biotechnology"},{"key":"2225_CR6","doi-asserted-by":"crossref","unstructured":"Danaei, G., Finucane, M. M., Lu, Y., Singh, G. M., Cowan, M. J., Paciorek, C. J., et al. (2011). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet, 378(9785), 31\u201340.","DOI":"10.1016\/S0140-6736(11)60679-X"},{"issue":"1","key":"2225_CR7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.diabres.2009.10.007","volume":"87","author":"JE Shaw","year":"2010","unstructured":"Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010). Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research and Clinical Practice, 87(1), 4\u201314.","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"5","key":"2225_CR8","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","volume":"27","author":"S Wild","year":"2004","unstructured":"Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004). Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 27(5), 1047\u20131053.","journal-title":"Diabetes Care"},{"issue":"12","key":"2225_CR9","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.2174\/092986711795496755","volume":"18","author":"MA Potenza","year":"2011","unstructured":"Potenza, M. A., Nacci, C., Gagliardi, S., & Montagnani, M. (2011). Cardiovascular complications in diabetes: lessons from animal models. Current Medicinal Chemistry, 18(12), 1806\u20131819.","journal-title":"Current Medicinal Chemistry"},{"issue":"1","key":"2225_CR10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11886-011-0238-6","volume":"14","author":"T Terry","year":"2012","unstructured":"Terry, T., Raravikar, K., Chokrungvaranon, N., & Reaven, P. D. (2012). Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT. Current Cardiology Reports, 14(1), 79\u201388.","journal-title":"Current Cardiology Reports"},{"key":"2225_CR11","doi-asserted-by":"crossref","unstructured":"Buse, J. B., Ginsberg, H. N., Bakris, G. L., Clark, N. G., Costa, F., Eckel, R., et al. (2007). Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation, 115(1), 114\u2013126.","DOI":"10.1161\/CIRCULATIONAHA.106.179294"},{"key":"2225_CR12","doi-asserted-by":"crossref","unstructured":"Oguma, T., Kuriyama, C., Nakayama, K., Matsushita, Y., Yoshida, K., Kiuchi, S., et al. (2015). The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats. Journal of Pharmacological Sciences, 127(4), 456\u2013461.","DOI":"10.1016\/j.jphs.2015.03.006"},{"key":"2225_CR13","doi-asserted-by":"crossref","unstructured":"Hall, M. J., Adin, C. A., Borin-Crivellenti, S., Rudinsky, A. J., Rajala-Schultz, P., Lakritz, J., et al. (2015). Pharmacokinetics and pharmacodynamics of the glucagon-like peptide-1 analog liraglutide in healthy cats. Domestic Animal Endocrinology, 51, 114\u2013121.","DOI":"10.1016\/j.domaniend.2014.12.001"},{"issue":"5","key":"2225_CR14","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/1753-0407.12161","volume":"6","author":"X Ma","year":"2014","unstructured":"Ma, X., Guan, Y., & Hua, X. (2014). Glucagon-like peptide 1-potentiated insulin secretion and proliferation of pancreatic beta-cells. Journal of Diabetes, 6(5), 394\u2013402.","journal-title":"Journal of Diabetes"},{"key":"2225_CR15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/B978-0-12-800101-1.00002-8","volume":"121","author":"P Nadkarni","year":"2014","unstructured":"Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014). Regulation of glucose homeostasis by GLP-1. Progress in Molecular Biology and Translational Science, 121, 23\u201365.","journal-title":"Progress in Molecular Biology and Translational Science"},{"issue":"6","key":"2225_CR16","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio, L. L., & Drucker, D. J. (2007). Biology of incretins: GLP-1 and GIP. Gastroenterology, 132(6), 2131\u20132157.","journal-title":"Gastroenterology"},{"key":"2225_CR17","doi-asserted-by":"crossref","unstructured":"Hou, J., Yan, R., Ding, D., Yang, L., Wang, C., Wu, Z., et al. (2007). Oral administration of a fusion protein containing eight GLP-1 analogues produced in Escherichia coli BL21(DE3) in streptozotocin-induced diabetic rats. Biotechnology Letters, 29(10), 1439\u20131446.","DOI":"10.1007\/s10529-007-9427-1"},{"key":"2225_CR18","doi-asserted-by":"crossref","unstructured":"Hou, J., Yan, R., Yang, L., Wu, Z., Wang, C., Ding, D., et al. (2007). High-level expression of fusion protein containing 10 tandem repeated GLP-1 analogs in yeast Pichia pastoris and its biological activity in a diabetic rat model. Bioscience, Biotechnology, and Biochemistry, 71(6), 1462\u20131469.","DOI":"10.1271\/bbb.60694"},{"issue":"3","key":"2225_CR19","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.peptides.2004.10.003","volume":"26","author":"Y Liu","year":"2005","unstructured":"Liu, Y., Lu, W. L., Zhang, X., Wang, X. Q., Zhang, H., & Zhang, Q. (2005). Pharmacodynamics and pharmacokinetics of recombinant hirudin via four non-parenteral routes. Peptides, 26(3), 423\u2013430.","journal-title":"Peptides"},{"issue":"17","key":"2225_CR20","doi-asserted-by":"crossref","first-page":"10839","DOI":"10.1016\/S0021-9258(18)99095-2","volume":"266","author":"JY Chang","year":"1991","unstructured":"Chang, J. Y. (1991). Stability of hirudin, a thrombin-specific inhibitor. The structure of alkaline-inactivated hirudin. The Journal of Biological Chemistry, 266(17), 10839\u201310843.","journal-title":"The Journal of Biological Chemistry"},{"issue":"1","key":"2225_CR21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0167-4889(91)90046-Z","volume":"1095","author":"A Donella-Deana","year":"1991","unstructured":"Donella-Deana, A., Varro, A., Dockray, G. J., & Pinna, L. A. (1991). Substitution of phosphotyrosine for sulphotyrosine in biologically active peptides. Enzymatic phosphorylation of a progastrin peptide confers immunoreactivity reminiscent of the sulphated derivative. Biochimica et Biophysica Acta, 1095(1), 75\u201377.","journal-title":"Biochimica et Biophysica Acta"},{"key":"2225_CR22","doi-asserted-by":"crossref","unstructured":"Ni, Z., Zhang, Y., Wang, H., Wei, Y., Ma, B., Hao, J., et al. (2016). Construction of a fusion peptide 5rolGLP-HV and analysis of its therapeutic effect on type 2 diabetes mellitus and thrombosis in mice. Applied Biochemistry and Biotechnology, 179(1), 59\u201374.","DOI":"10.1007\/s12010-016-1979-x"},{"key":"2225_CR23","doi-asserted-by":"crossref","unstructured":"Barrett, Y. C., Wang, J., Song, Y., Pursley, J., Wastall, P., Wright, R., et al. (2012). A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. Thrombosis and Haemostasis, 107(5), 916\u2013924.","DOI":"10.1160\/TH11-09-0634"},{"key":"2225_CR24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev-pharmtox-010510-100540","volume":"51","author":"M Rowland","year":"2011","unstructured":"Rowland, M., Peck, C., & Tucker, G. (2011). Physiologically-based pharmacokinetics in drug development and regulatory science. Annual Review of Pharmacology and Toxicology, 51, 45\u201373.","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"8","key":"2225_CR25","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1007\/s12010-011-9210-6","volume":"164","author":"R Kumar","year":"2011","unstructured":"Kumar, R., Sharma, B., Tomar, N. R., Roy, P., Gupta, A. K., & Kumar, A. (2011). In vivo evaluation of hypoglycemic activity of Aloe spp. and identification of its mode of action on GLUT-4 gene expression in vitro. Applied Biochemistry and Biotechnology, 164(8), 1246\u20131256.","journal-title":"Applied Biochemistry and Biotechnology"},{"key":"2225_CR26","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejphar.2015.01.027","volume":"750","author":"MA Morsy","year":"2015","unstructured":"Morsy, M. A., Heeba, G. H., & Mahmoud, M. E. (2015). Ameliorative effect of eprosartan on high-fat diet\/streptozotocin-induced early diabetic nephropathy in rats. European Journal of Pharmacology, 750, 90\u201397.","journal-title":"European Journal of Pharmacology"},{"key":"2225_CR27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.neuropharm.2014.06.026","volume":"86","author":"R Lennox","year":"2014","unstructured":"Lennox, R., Porter, D. W., Flatt, P. R., Holscher, C., Irwin, N., & Gault, V. A. (2014). Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice. Neuropharmacology, 86, 22\u201330.","journal-title":"Neuropharmacology"},{"issue":"3 Suppl","key":"2225_CR28","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2009.12.004","volume":"123","author":"M Stolar","year":"2010","unstructured":"Stolar, M. (2010). Glycemic control and complications in type 2 diabetes mellitus. The American Journal of Medicine, 123(3 Suppl), S3\u201311.","journal-title":"The American Journal of Medicine"},{"issue":"3","key":"2225_CR29","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.pharmthera.2006.11.007","volume":"113","author":"ME Doyle","year":"2007","unstructured":"Doyle, M. E., & Egan, J. M. (2007). Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacology & Therapeutics, 113(3), 546\u2013593.","journal-title":"Pharmacology & Therapeutics"},{"issue":"2\u20133","key":"2225_CR30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cbi.2008.10.039","volume":"179","author":"Y Ou","year":"2009","unstructured":"Ou, Y., Geng, P., Liao, G. Y., Zhou, Z., & Wu, W. T. (2009). Intracellular GSH and ROS levels may be related to galactose-mediated human lens epithelial cell apoptosis: role of recombinant hirudin variant III. Chemico-Biological Interactions, 179(2\u20133), 103\u2013109.","journal-title":"Chemico-Biological Interactions"},{"key":"2225_CR31","doi-asserted-by":"crossref","unstructured":"Park, S. H., Park, J. H., Shim, H. M., Na, A. Y., Bae, K. C., Lim, J. G., et al. (2015). Protection of pancreatic beta-cells against glucotoxicity by short-term treatment with GLP-1. Biochemical and Biophysical Research Communications, 459(4), 561\u2013567.","DOI":"10.1016\/j.bbrc.2015.02.139"},{"issue":"6","key":"2225_CR32","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","volume":"17","author":"JE Campbell","year":"2013","unstructured":"Campbell, J. E., & Drucker, D. J. (2013). Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metabolism, 17(6), 819\u2013837.","journal-title":"Cell Metabolism"}],"container-title":["Applied Biochemistry and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12010-016-2225-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12010-016-2225-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12010-016-2225-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T21:23:32Z","timestamp":1657229012000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12010-016-2225-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,7]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["2225"],"URL":"https:\/\/doi.org\/10.1007\/s12010-016-2225-2","relation":{},"ISSN":["0273-2289","1559-0291"],"issn-type":[{"value":"0273-2289","type":"print"},{"value":"1559-0291","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,7]]}}}